PARP Inhibitor Biomarkers Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	176 Pages	Coherent Market Insights	June, 2023	CMI18107799

Best Price Guarantee
Price	from $4,500
Length	176 Pages
Publisher	Coherent Market Insights
Published Date	June, 2023
SKU	CMI18107799

PARP Inhibitor Biomarkers Market, by Product & Services (Product Type (Kits and Assays) and Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing and Others)), by Application (Breast Cancer, Ovarian Cancer, and Others (Prostate, Pancreatic, etc.) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Genomic integrity of the human cells helps the human mechanism to perform all its physiological and immunological functions optimally. When genomic integrity is affected due to genomic instability some life-threatening changes occur in the human body affecting immunological functions significantly. When the genomic integrity of a human cell reaches beyond its peak level it causes cancer initiation and progression. The cancer cells survive and multiply with the help of proteins such as Poly(ADP-ribose) polymerase (PARP). Poly(ADP-ribose) polymerase (PARP) is a type of protein that aids cancer cells to repair themselves. It is responsible for essential cellular functions such as maintaining genomic integrity, DNA repair, and programmed cell death. DNA repair is a set of processes adopted by human cells to identify and regulate damage to the DNA molecules while keeping the genome integrity and genome stability intact. Poly(ADP-ribose) polymerase (PARP) inhibitor is a type of drug therapy that works by preventing enzymes involved in DNA repair processes thereby limiting the growth of cancer cells.

Market Dynamics

The key market players are focusing on adoption of growth organic strategies such launching of new PARP inhibitor biomarkers, which is attributed to the growth of global PARP Inhibitor Biomarkers market. For instance, in March 2020, BD (Becton, Dickinson and Company) is a medical technology company, and BioMedomics, a privately held, U.S.-based clinical diagnostics company, announced the release of a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to PARP biomarker test in as little as 15 minutes.

Key features of the study:

This report provides an in-depth analysis of the global PARP Inhibitor Biomarkers market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global PARP Inhibitor Biomarkers market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include include Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc. Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, Bio Rad Laboratories Inc., Exagen Inc.,Genway Biotech, Inc., Microdrop LLC (imaware), Svar Life Science AB and Thermo Fisher Scientific Inc.
Global PARP Inhibitor Biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP Inhibitor Biomarkers

Detailed Segmentation:

Global PARP Inhibitor Biomarkers Market, By Product Type and Services :
Product Type
Kits
Assays
Services
BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others
Global PARP Inhibitor Biomarkers Market, By Application :
Breast Cancer
Ovarian Cancer
Others
Global PARP Inhibitor Biomarkers, By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles
Myriad Genetics, Inc.
F. Hoffmann-La Roche AG
Invitae Corporation
NeoGenomics Laboratories, Inc.
BPS Bioscience, Inc.
Antibodies Inc.
Networks LLC
Beckman Coulter, Inc.
Euro Diagnostica AB
F. Hoffmann-La Roche Ltd.
Qiagen NV
Siemens Healthcare GmbH
Bio Rad Laboratories Inc.
Exagen Inc.
Genway Biotech, Inc.
Microdrop LLC (imaware)
Svar Life Science AB
Thermo Fisher Scientific Inc.

1. Research Objective and Assumption: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snippet, By Product Type and Services; Market Snippet, By Application; Market Snippet, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Recent Product Launches; Epidemiology; Merger, Acquisition, and Collaborations; Regulatory Scenario; Key Developments; PEST Analysis
4. Global PARP inhibitor biomarkers Market – COVID-19 Impact Analysis: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global PARP inhibitor biomarkers Market, By Product Type and Services, 2018 – 2030 (US$ Mn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; Product Type; Tests; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Segment Trends; Kits; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Segment Trends; Services; BRCA 1 & 2 Testing; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); HRD Testing; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); HRR Testing; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
6. Global PARP inhibitor biomarkers Market, By Application, 2018 – 2030 (US$ Mn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; Breast Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Ovarian Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
7. Global PARP inhibitor biomarkers Market, By Regions, 2018 – 2030 (US$ Mn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; North America; Introduction; Market Size and Forecast, By Product Type and Services, and Y-o-Y Growth 2018 – 2030, (US$ Mn); Market Size and Forecast, By Application , and Y-o-Y Growth 2018 – 2030, (US$ Mn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Mn); U.S.; Canada; Europe; Introduction; Market Size and Forecast, By Product Type and Services, and Y-o-Y Growth 2018 – 2030, (US$ Mn); Market Size and Forecast, By Application , and Y-o-Y Growth 2018 – 2030, (US$ Mn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Mn); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, By Product Type and Services, and Y-o-Y Growth 2018 – 2030, (US$ Mn); Market Size and Forecast, By Application , and Y-o-Y Growth 2018 – 2030, (US$ Mn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Mn); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Latin America; Introduction; Market Size and Forecast, By Product Type and Services, and Y-o-Y Growth 2018 – 2030, (US$ Mn); Market Size and Forecast, By Application , and Y-o-Y Growth 2018 – 2030, (US$ Mn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Mn); Brazil; Mexico; Argentina; Rest of Latin America; Middle East; Introduction; Market Size and Forecast, By Product Type and Services, and Y-o-Y Growth 2018 – 2030, (US$ Mn); Market Size and Forecast, By Application , and Y-o-Y Growth 2018 – 2030, (US$ Mn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Mn); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, By Product Type and Services, and Y-o-Y Growth 2018 – 2030, (US$ Mn); Market Size and Forecast, By Application , and Y-o-Y Growth 2018 – 2030, (US$ Mn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Mn); North Africa; Central Africa; South Africa
8. Competitive Landscape: Company Profiles; Abbott Diagnostics (Abbott Laboratories); Myriad Genetics, Inc.; F. Hoffmann-La Roche AG; Invitae Corporation; NeoGenomics Laboratories, Inc.; BPS Bioscience; Antibodies Inc.; Networks LLC; Beckman Coulter, Inc.; Euro Diagnostica AB, F.; Hoffmann-La Roche Ltd.; Qiagen NV; Siemens Healthcare GmbH; Augurex Life Sciences Corp.; Thermo Fisher Scientific Inc.; Bio Rad Laboratories Inc.; Exagen Inc.; Genway Biotech, Inc.; Microdrop LLC (imaware); Svar Life Science AB
9. Section: References; Research Methodology; About us and Sales Contact; *Browse 34 market data tables and 26 figures on “Global PARP inhibitor biomarkers Market – Global forecast to 2030